Crossmark

Resistance is futile with fourth-generation EGFR inhibitors

Crossref DOI link: https://doi.org/10.1038/s43018-022-00365-2

Published Online: 2022-04-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Marasco, Michelangelo

Misale, Sandra https://orcid.org/0000-0002-6031-0137
License Information

Text and Data Mining valid from 2022-04-14

Version of Record valid from 2022-04-14
More Information

Article History

First Online: 14 April 2022

Competing interests

: S.M. has served as a consultant for Boehringer Ingelheim. M.M. declares no competing interests.